Entrada Therapeutics Q3 2026 Earnings Date & Estimates

Entrada Therapeutics (NASDAQ:TRDA) is a biotechnology company focused on developing medicines that address diseases caused by genetic abnormalities. The company’s research centers on its proprietary Endosomal Escape Vehicle (EEV) platform, which is designed to transport therapeutic cargo into cells and release it from endosomes, potentially enabling treatment of targets that have been difficult to reach with conventional drug-delivery approaches.

Entrada is developing EEV-based therapeutics using modalities such as oligonucleotides, including compounds intended to modify RNA or influence gene expression. Its pipeline has included programs for rare genetic and neuromuscular disorders, including Duchenne muscular dystrophy and myotonic dystrophy type 1. The company’s Duchenne programs are designed to promote exon skipping for specific genetic mutations, with the goal of helping cells produce a functional form of dystrophin.

Founded in 2016 and headquartered in Boston, Massachusetts, Entrada conducts research and clinical development aimed at serving patients with serious diseases in the United States and other global markets. As a clinical-stage biotechnology company, its products remain in development and are subject to the outcomes of clinical trials, regulatory review and other development requirements.